Bradley Dye, Daniel Gromer, Bibi Maryam, Emily A Siegrist, Joseph Sassine
{"title":"嵌合抗原受体T细胞治疗和双特异性抗体的感染并发症综述。","authors":"Bradley Dye, Daniel Gromer, Bibi Maryam, Emily A Siegrist, Joseph Sassine","doi":"10.1016/j.amjms.2025.10.007","DOIUrl":null,"url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T cell therapy has shifted the therapeutic landscape of hematological malignancies in the last decade, and bispecific antibodies (BsAb) are an emerging treatment for this patient population. Immunosuppression associated with these therapies can lead to a variety of infectious complications. In this narrative review, we explore the epidemiology, risk factors and prevention of bacterial, viral and fungal infections after CAR T cell and BsAb therapy.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Infectious Complications of Chimeric Antigen Receptor T Cell Therapy and Bispecific Antibodies - A Review.\",\"authors\":\"Bradley Dye, Daniel Gromer, Bibi Maryam, Emily A Siegrist, Joseph Sassine\",\"doi\":\"10.1016/j.amjms.2025.10.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chimeric antigen receptor (CAR) T cell therapy has shifted the therapeutic landscape of hematological malignancies in the last decade, and bispecific antibodies (BsAb) are an emerging treatment for this patient population. Immunosuppression associated with these therapies can lead to a variety of infectious complications. In this narrative review, we explore the epidemiology, risk factors and prevention of bacterial, viral and fungal infections after CAR T cell and BsAb therapy.</p>\",\"PeriodicalId\":94223,\"journal\":{\"name\":\"The American journal of the medical sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The American journal of the medical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.amjms.2025.10.007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of the medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.amjms.2025.10.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Infectious Complications of Chimeric Antigen Receptor T Cell Therapy and Bispecific Antibodies - A Review.
Chimeric antigen receptor (CAR) T cell therapy has shifted the therapeutic landscape of hematological malignancies in the last decade, and bispecific antibodies (BsAb) are an emerging treatment for this patient population. Immunosuppression associated with these therapies can lead to a variety of infectious complications. In this narrative review, we explore the epidemiology, risk factors and prevention of bacterial, viral and fungal infections after CAR T cell and BsAb therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
